Top 5 HIV Articles in 2023
This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.
- T Cell Activation Seen as Insufficient to Drive HIV Infection
Chronic T cell immune activation and inflammation are key features of HIV-1 infection in humans and simian immunodeficiency virus (SIV) infection of rhesus macaques, and a group of researchers from University of Pittsburgh looked to see if T cell activation is sufficient to drive SIV disease progression.
Read here - Immune Checkpoint Inhibitors Study for People Living With HIV Shows Promising Results
Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.
Read here - HIV Stays Controlled in These Individuals Even After They Stop Treatment. Understanding Why Could Provide Clues to a ‘Functional Cure'
A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.
Read here - Advancing Options for Gene Editing for HIV-1
CRISPR gene-editing therapy is predicted to cost about $1 million dollars per person which is considerably more expensive than keeping a patient on ART for the rest of their life.
Read here - On Long-Term Treatment, Piggybacking on Hepatitis C Eradication and the ‘Biggest Buzz' in HIV: A Conversation with Angel I. Ribó, PA-C, MPAS
Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.
Read here
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 31st 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
July 31st 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
